SMMT
Summit Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$15.57
+6.43%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$14.90
From 52W high−40.98%
Volume6.13M
Market cap$12.42B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$14.90
From 52W high
−40.98%
Volume
6.13M
Market cap
$12.42B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−13.7x
P/E (TTM)
—
RSI (14)
46.6
MomentumView details →
1D Return
+6.43%
YTD Return
−10.27%
SummaryUpdated Jun 1, 2026
Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company founded in 2003 and headquartered in Cambridge, Massachusetts. Originally focused on developing treatments for infectious diseases, the company underwent a strategic transformation in 2022 when it pivoted entirely to oncology. Summit acquired the rights to develop and commercialize ivonescimab, a promising cancer immunotherapy, through a landmark $500 million licensing agreement with Chinese biotech company Akeso. The company is now focused exclusively on advancing this bispecific antibody through late-stage clinical trials for various cancer indications, particularly non-small cell lung cancer.
Similar companies
Latest newsMore news →
AstraZeneca and Daiichi Sankyo entered into a clinical collaboration with Summit Therapeutics to test Datroway in combination with ivonescimab across multiple tumour types, including lung and breast cancers.18d agoSummit Therapeutics shares surged 23%, marking their largest intraday gain since April 2025.20d agoAkeso shares surged as much as 15.65% to HK$106.4 in morning trading after its overseas partner Summit Therapeutics received a US$2 billion strategic investment from AstraZeneca.21d ago